AIM ImmunoTech Reports Increased Net Loss and Strategic Focus on Ampligen for Pancreatic Cancer

AIM ImmunoTech Inc. reported a net loss of $3.8 million for the quarter ending June 30, 2026, compared to a net loss of $2.8 million for the same period in 2025, marking a 35.6% increase in losses. Total revenues for the quarter were $26,000, a slight increase from $25,000 in the previous year. The company's total costs and expenses rose to $3.5 million, up 32.5% from $2.7 million, primarily due to increased general and administrative expenses, which nearly doubled to $2.9 million. Research and development costs decreased significantly by 49.8% to $589,000, reflecting a strategic shift in focus towards ongoing clinical trials for Ampligen, particularly in pancreatic cancer.

For the six months ending June 30, 2026, AIM ImmunoTech reported a net loss of $6.8 million, slightly higher than the $6.5 million loss recorded in the same period in 2025. Total revenues for the first half of 2026 were $48,000, up from $41,000 in 2025. The company’s total costs and expenses decreased by 8.2% to $5.8 million, driven by lower research and development expenditures, which fell by 52.5% to $1.1 million. The reduction in R&D spending is attributed to the completion of a Phase II study and a strategic pivot towards a European pancreatic cancer study funded by a grant.

AIM ImmunoTech has made significant strides in its operational strategy, including a rights offering completed in March 2026 that raised $1.8 million, and a series of equity transactions that generated approximately $10.4 million in gross proceeds. The company also engaged in a warrant exercise inducement transaction in May 2026, which resulted in the immediate exercise of over 7.4 million warrants, generating approximately $3.6 million. These financing activities have bolstered the company’s cash position, which increased to $9.9 million as of June 30, 2026, compared to $3.0 million at the end of 2025.

In terms of strategic developments, AIM ImmunoTech is focusing its efforts on the development of Ampligen for the treatment of late-stage pancreatic cancer, a decision supported by promising clinical trial results. The company is currently conducting the DURIPANC study, which combines Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi. As of June 30, 2026, all subjects have been enrolled in this study, with results expected to be published later this year. Additionally, AIM has entered into a collaboration with Thermo Fisher Scientific to design a Phase 3 clinical trial for Ampligen in pancreatic cancer.

Looking ahead, AIM ImmunoTech anticipates that its ongoing clinical trials and strategic partnerships will be critical in advancing its product pipeline. However, the company acknowledges the need for additional funding to support its operations and clinical development activities, as it does not currently generate significant revenue. The management remains committed to maintaining compliance with NYSE American listing requirements and is focused on achieving its long-term business objectives.